| COVID-19 in patients with lung cancer J Luo, H Rizvi, IR Preeshagul, JV Egger, D Hoyos, C Bandlamudi, ... Annals of Oncology 31 (10), 1386-1396, 2020 | 319 | 2020 |
| MET-dependent solid tumours—molecular diagnosis and targeted therapy R Guo, J Luo, J Chang, N Rekhtman, M Arcila, A Drilon Nature Reviews Clinical Oncology 17 (9), 569-587, 2020 | 264 | 2020 |
| Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers J Luo, H Rizvi, JV Egger, IR Preeshagul, JD Wolchok, MD Hellmann Cancer discovery 10 (8), 1121-1128, 2020 | 261* | 2020 |
| Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade Q Zhang, J Luo, S Wu, H Si, C Gao, W Xu, SE Abdullah, BW Higgs, ... Cancer Discovery 10 (12), 1842-1853, 2020 | 257 | 2020 |
| Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L) 1 blockade in patients with non-small cell lung cancer RS Vanguri, J Luo, AT Aukerman, JV Egger, CJ Fong, N Horvat, ... Nature cancer 3 (10), 1151-1164, 2022 | 191 | 2022 |
| Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L) 1 blockade in NSCLC MD Hellmann, BY Nabet, H Rizvi, AA Chaudhuri, DK Wells, MPS Dunphy, ... Clinical Cancer Research 26 (12), 2849-2858, 2020 | 117 | 2020 |
| AMP-activated protein kinase directly phosphorylates and destabilizes hedgehog pathway transcription factor GLI1 in medulloblastoma YH Li, J Luo, YYC Mosley, VE Hedrick, LN Paul, J Chang, GJ Zhang, ... Cell reports 12 (4), 599-609, 2015 | 91 | 2015 |
| Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events J Luo, JA Beattie, P Fuentes, H Rizvi, JV Egger, JA Kern, DYM Leung, ... Journal of Thoracic Oncology 16 (10), 1759-1764, 2021 | 81 | 2021 |
| Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non–Small Cell Lung Cancer J Luo, VL Martucci, Z Quandt, S Groha, MH Murray, CM Lovly, H Rizvi, ... Clinical Cancer Research 27 (18), 5131-5140, 2021 | 66 | 2021 |
| Deep learning to estimate RECIST in patients with NSCLC treated with PD-1 blockade KC Arbour, AT Luu, J Luo, H Rizvi, AJ Plodkowski, M Sakhi, KB Huang, ... Cancer discovery 11 (1), 59-67, 2021 | 60 | 2021 |
| Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer B Ricciuti, JV Alessi, A Elkrief, X Wang, A Cortellini, YY Li, VR Vaz, ... Annals of Oncology 33 (10), 1029-1040, 2022 | 59 | 2022 |
| Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial J Desai, G Alonso, SH Kim, A Cervantes, T Karasic, L Medina, ... Nature Medicine 30 (1), 271-278, 2024 | 53 | 2024 |
| Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥ 50%) non–small cell lung cancer and a poor performance status JV Alessi, B Ricciuti, E Jiménez-Aguilar, F Hong, Z Wei, M Nishino, ... Journal for immunotherapy of cancer 8 (2), e001007, 2020 | 52 | 2020 |
| Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer D Memon, AJ Schoenfeld, D Ye, G Fromm, H Rizvi, X Zhang, MR Keddar, ... Cancer Cell 42 (2), 209-224. e9, 2024 | 46 | 2024 |
| Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade J Beattie, H Rizvi, P Fuentes, J Luo, A Schoenfeld, IH Lin, M Postow, ... Journal for ImmunoTherapy of Cancer 9 (2), e001884, 2021 | 46 | 2021 |
| Treatment of nonmetastatic castration-resistant prostate cancer J Luo, TM Beer, JN Graff Oncology 30 (4), 336-336, 2016 | 43 | 2016 |
| Overcoming KRAS-Mutant Lung Cancer J Luo, J Ostrem, B Pellini, D Imbody, Y Stern, HS Solanki, EB Haura, ... American Society of Clinical Oncology Educational Book 41, 700-710, 2022 | 34 | 2022 |
| Deciphering radiological stable disease to immune checkpoint inhibitors J Luo, S Wu, H Rizvi, Q Zhang, JV Egger, JC Osorio, AJ Schoenfeld, ... Annals of Oncology 33 (8), 824-835, 2022 | 31 | 2022 |
| High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience AJ Piper-Vallillo, JK Rotow, JV Aredo, K Shaverdashvili, J Luo, ... JTO Clinical and Research Reports 3 (6), 100328, 2022 | 27 | 2022 |
| Current patterns of care for patients with extensive-stage SCLC: survey of US radiation oncologists on their recommendations regarding prophylactic cranial irradiation A Jain, J Luo, Y Chen, MA Henderson, CR Thomas Jr, T Mitin Journal of Thoracic Oncology 11 (8), 1305-1310, 2016 | 27 | 2016 |